Categories: News

Dr. Gregg Sturrus’ TEDx Talk(R) Features Halberd’s Extracorporeal Treatment of Neurodegenerative Diseases

JACKSON CENTER, PA / ACCESSWIRE / April 29, 2022 / A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. The video can be found here. https://www.youtube.com/watch?v=Tfl2x7t4FHo

Dr. Sturrus, in his talk, provided a brief history of the evolution of the technology and outlines the innovative Halberd approach to potentially treating neurodegenerative diseases, as well as other diseases.

Dr. Sturrus is Chair of the Physics, Astronomy, Geology and Earth Sciences department at Youngstown State University. Dr. Sturrus has over 30 years of experience in the areas of atomic physics, radio frequency and laser research.

To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/699392/Dr-Gregg-Sturrus-TEDx-TalkR-Features-Halberds-Extracorporeal-Treatment-of-Neurodegenerative-Diseases

Staff

Recent Posts

Medsien Launches Fully Managed Advanced Primary Care Management (APCM) Solution to Power the Next Generation of Primary Care

Medsien's Advanced Primary Care Management (APCM) program transforms chronic care with fast deployment, smart automation…

2 hours ago

Hemostemix Closes $469,366 Private Placement

Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…

5 hours ago

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr.…

5 hours ago

Virbac : Declaration of the number of shares and voting rights 06/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of…

5 hours ago